In this talk, we will discuss the following topics:
Johnson and Johnson's vaccine is different from others because it is a single-shot vaccine.
Phase III trial interim results of the J&J vaccines showing
a) 100% protection from COVID related deaths
b) 85% protection from the severe COVID disease
c) 66% overall efficacy
Countries in which the vaccine trial is conducted
The reason for lesser efficacy in South Africa
Side effects are similar to a placebo that is not too bad
Mobeen Syed M.D, MS Graduated from King Edward Medical University. Entrepreneur, Medical Educator, CEO and founder of Drbeen corp.